GRANULES Granules India Q4 FY26 results (Jan–Mar 2026) and concall
Granules India reported a strong Q4 and FY26, marked by significant revenue growth, margin expansion, and debt reduction. The Peptide CDMO business turned EBITDA positive, and the company made strategic progress in its U.S. generics and controlled substances portfolio. However, external cost pressures and regulatory uncertainties, particularly regarding the Gagillapur FDA re-inspection and DCDA project, remain areas of concern.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 14.2%, net profit up 5.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 568 | 842 | 768 | 810 | 892 +57% | 895 +6% | 877 +14% |
| EBITDA | 103 | 168 | 117 | 144 | 211 +105% | 194 +15% | 175 +50% |
| Net profit | 41 | 90 | 94 | 69 | 121 +195% | 112 +24% | 99 +5% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
